AP3268A - Co-crystals and salts of CCR3-inhibitors - Google Patents

Co-crystals and salts of CCR3-inhibitors

Info

Publication number
AP3268A
AP3268A AP2013006679A AP2013006679A AP3268A AP 3268 A AP3268 A AP 3268A AP 2013006679 A AP2013006679 A AP 2013006679A AP 2013006679 A AP2013006679 A AP 2013006679A AP 3268 A AP3268 A AP 3268A
Authority
AP
ARIPO
Prior art keywords
ccr3
crystals
inhibitors
salts
Prior art date
Application number
AP2013006679A
Other languages
English (en)
Other versions
AP2013006679A0 (en
Inventor
Uwe Stertz
Thorsten Pachur
Manuel Henry
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2013006679A0 publication Critical patent/AP2013006679A0/xx
Application granted granted Critical
Publication of AP3268A publication Critical patent/AP3268A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2013006679A 2010-10-07 2011-10-06 Co-crystals and salts of CCR3-inhibitors AP3268A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10186901 2010-10-07
PCT/EP2011/067437 WO2012045803A1 (en) 2010-10-07 2011-10-06 Co-crystals and salts of ccr3-inhibitors

Publications (2)

Publication Number Publication Date
AP2013006679A0 AP2013006679A0 (en) 2013-01-31
AP3268A true AP3268A (en) 2015-05-31

Family

ID=44741339

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013006679A AP3268A (en) 2010-10-07 2011-10-06 Co-crystals and salts of CCR3-inhibitors

Country Status (36)

Country Link
US (3) US8742115B2 (ko)
EP (1) EP2625174B1 (ko)
JP (1) JP5794713B2 (ko)
KR (3) KR102239690B1 (ko)
CN (1) CN103140486B (ko)
AP (1) AP3268A (ko)
AR (1) AR083353A1 (ko)
AU (1) AU2011311530B2 (ko)
BR (2) BR112013008211B1 (ko)
CA (1) CA2807255C (ko)
CL (1) CL2013000488A1 (ko)
CO (1) CO6710910A2 (ko)
CY (1) CY1116168T1 (ko)
DK (1) DK2625174T3 (ko)
EA (1) EA029097B1 (ko)
EC (1) ECSP13012600A (ko)
ES (1) ES2535264T3 (ko)
GE (1) GEP20166488B (ko)
HR (1) HRP20150419T1 (ko)
HU (1) HUE024540T2 (ko)
IL (1) IL224269A (ko)
MA (1) MA34545B1 (ko)
ME (1) ME02040B (ko)
MX (1) MX2013003785A (ko)
MY (1) MY167898A (ko)
NZ (1) NZ605827A (ko)
PE (1) PE20140188A1 (ko)
PL (1) PL2625174T3 (ko)
PT (1) PT2625174E (ko)
RS (1) RS53858B1 (ko)
SG (1) SG188949A1 (ko)
SI (1) SI2625174T1 (ko)
TW (1) TWI546294B (ko)
UA (1) UA109290C2 (ko)
UY (1) UY33655A (ko)
WO (1) WO2012045803A1 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US20200054622A1 (en) * 2017-04-05 2020-02-20 Alkahest, Inc. Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
US11382907B2 (en) * 2017-04-05 2022-07-12 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
CN110650740A (zh) * 2017-04-05 2020-01-03 万能溶剂有限公司 使用ccr3抑制剂治疗视网膜相关疾病的方法和组合物
AU2018347447B2 (en) * 2017-10-13 2024-03-07 Alkahest, Inc. Methods and compositions for treating pruritus, xerosis, and associated disease using CCR3-inhibitors
CN112469439A (zh) 2018-05-15 2021-03-09 万能溶剂有限公司 用白三烯a4水解酶调节剂治疗衰老相关性疾病
CN112789044A (zh) * 2018-09-26 2021-05-11 万能溶剂有限公司 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物
WO2021252647A1 (en) * 2020-06-11 2021-12-16 Alkahest Inc. Methods of improving retina-associated disease outcome using ccr3-inhibitors
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007116313A2 (en) * 2006-04-12 2007-10-18 Pfizer Limited Pyrrolidine derivatives as modulators of chemokine ccr5 receptors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7907121L (sv) 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
EP1047675A1 (en) 1998-01-21 2000-11-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU2654399A (en) 1998-02-02 1999-08-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
JP2005518424A (ja) * 2001-11-29 2005-06-23 シェーリング　コーポレイション Ａｉｄｓおよび関連するｈｉｖ感染の処置のためのｃｃｒ５−アンタゴニストとしての４（（ｚ）−（４−ブロモフェニル）エトキシイミノ）メチル）−１’−（（２，４−ジメチル−１−オキシド−３−ピリジニルカルボニル）−４’−メチル−１，４’ビピペリジンの薬学的塩の調製
CA2514092C (en) 2003-01-21 2013-03-19 S.S.C.I., Inc. Novel cocrystallization of hydrochloric acid salt of an active agent
WO2005040129A2 (en) 2003-10-24 2005-05-06 F. Hoffmann-La Roche Ag Ccr3 receptor antagonists
ATE428422T1 (de) 2004-02-05 2009-05-15 Schering Corp Piperidin-derivate als ccr3-antagonisten
WO2006007448A2 (en) 2004-06-17 2006-01-19 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
JP2006137718A (ja) 2004-11-12 2006-06-01 Astellas Pharma Inc インドール若しくはインダゾール誘導体
WO2006083390A2 (en) 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
JP3701964B1 (ja) 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
ATE476424T1 (de) 2006-04-20 2010-08-15 Hoffmann La Roche Diazepanderivate als modulatoren von chemokinrezeptoren
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
TW201000446A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007116313A2 (en) * 2006-04-12 2007-10-18 Pfizer Limited Pyrrolidine derivatives as modulators of chemokine ccr5 receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TING P C ET AL: "The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 15, no. 5, 1 March 2005 (2005-03-01), pages 1375-1378, XP025314524 *

Also Published As

Publication number Publication date
BR112013008211B1 (pt) 2021-08-24
MX2013003785A (es) 2013-06-05
AU2011311530A1 (en) 2013-01-31
CN103140486A (zh) 2013-06-05
HRP20150419T1 (hr) 2015-05-22
SG188949A1 (en) 2013-05-31
CA2807255A1 (en) 2012-04-12
BR122021010665B1 (pt) 2022-03-15
US20150105371A1 (en) 2015-04-16
KR20130118313A (ko) 2013-10-29
KR102239690B1 (ko) 2021-04-13
CA2807255C (en) 2018-11-13
US20120264729A1 (en) 2012-10-18
HUE024540T2 (hu) 2016-01-28
KR102163874B1 (ko) 2020-10-12
KR20180005717A (ko) 2018-01-16
CN103140486B (zh) 2016-08-03
BR112013008211A2 (pt) 2016-06-21
PL2625174T3 (pl) 2015-06-30
WO2012045803A1 (en) 2012-04-12
BR112013008211A8 (pt) 2017-10-10
KR20190104645A (ko) 2019-09-10
EP2625174B1 (en) 2015-01-21
PE20140188A1 (es) 2014-02-26
JP2013542207A (ja) 2013-11-21
UA109290C2 (uk) 2015-08-10
US8742115B2 (en) 2014-06-03
AP2013006679A0 (en) 2013-01-31
TWI546294B (zh) 2016-08-21
EA201300436A8 (ru) 2018-01-31
RS53858B1 (en) 2015-08-31
EA029097B1 (ru) 2018-02-28
AU2011311530B2 (en) 2015-04-09
US9233950B2 (en) 2016-01-12
TW201305134A (zh) 2013-02-01
CL2013000488A1 (es) 2013-07-05
GEP20166488B (en) 2016-06-10
IL224269A (en) 2017-08-31
UY33655A (es) 2012-04-30
ECSP13012600A (es) 2013-07-31
PT2625174E (pt) 2015-03-09
ES2535264T3 (es) 2015-05-07
US20140135307A1 (en) 2014-05-15
AR083353A1 (es) 2013-02-21
SI2625174T1 (sl) 2015-03-31
MY167898A (en) 2018-09-26
NZ605827A (en) 2015-09-25
JP5794713B2 (ja) 2015-10-14
CY1116168T1 (el) 2017-02-08
EA201300436A1 (ru) 2013-08-30
ME02040B (me) 2015-05-20
KR101844215B1 (ko) 2018-04-03
EP2625174A1 (en) 2013-08-14
DK2625174T3 (da) 2015-02-02
CO6710910A2 (es) 2013-07-15
MA34545B1 (fr) 2013-09-02

Similar Documents

Publication Publication Date Title
AP3268A (en) Co-crystals and salts of CCR3-inhibitors
IL226489A0 (en) Salts and crystalline forms of a substance
ZA201308851B (en) Storage of respiratory produce
IL226477A (en) Salts and polymorphic forms of Aptinib
HK1178149A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
HK1183014A1 (en) Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2-
EP2772483A4 (en) 4-AMINOCARBAZOLE COMPOUND AND USE THEREOF
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2548859A4 (en) PREPARATION OF METHYL-D3-AMINE AND SALTS THEREOF
ZA201206456B (en) Uses of dgati inhibitors
ZA201209666B (en) Salts and polymorhs of dexrabeprazole
EP2702034A4 (en) PREPARATION OF FINGOLIMOD AND ITS SALTS
HK1207643A1 (en) Amides of 2-amino-4-arylthiazole compounds and their salts 2--4-
EP2581369A4 (en) METHOD OF MANUFACTURING DRONEDARON AND ITS SALTS
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2601178A4 (en) SALTS OF LAPATINIB
ZA201207945B (en) Salts of dexlansoprazole and their preparation
RS55226B1 (sr) Kokristali ciprodinila
HU1000688D0 (en) Use of trifluoro-phal
GB201010704D0 (en) Storage of respiratory produce
GB201004359D0 (en) Storage of respiratory produce
GB201011957D0 (en) Co-crystals
GB201011958D0 (en) Co-crystals
GB201005627D0 (en) Co-crystals